Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Boston Scientific (BSX) Any Comments??? -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (767)	9/19/2001 10:18:09 AM
From: Lighthouse	Read Replies (1) \| Respond to of 798

BSX catches a bone from the courts. I thought MDT and BSX would settle this Rapid Exchange case and thereby give BSX some royalty income. But they got an injuction on certain products - very unexpected from my point of view. Nice win. Next big point will be the longer term follow up to JNJ's coated stent trial. I find it hard to believe that JNJ can carry a "Zero Restenosis" rate for their stent. If they can it's lights out for everyone else (MDT, JNJ, GDT). If the restenosis comes in somewhere between 0% and 5%, then the game is afoot. MDT is way behind in the race for coated stents and now they have no rapid exchange techology. AVE division sucking wind. Cheers,